Nausea · adults with schizophrenia
Noradrenaline reuptake inhibitors showed no clear difference in adverse effects: Nausea ‐ short term (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
Selective serotonin reuptake inhibitors probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
Serotonin‐norepinephrine reuptake inhibitors showed no clear difference in number of dropouts due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · cannabis dependence
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants experiencing adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Acceptability ‐ dropouts due to adverse effects · adults (aged 18 years+) with depression in bipolar disorder
Memantine showed no clear difference in acceptability: dropouts due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Acceptability ‐ dropouts due to adverse effects · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ dropouts due to adverse effects · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ dropouts due to adverse effects · participants with panic disorder
It is very uncertain whether rTMS + pharmacotherapy changes acceptability: dropouts for adverse effects number of dropouts compared with sham rTMS + pharmacotherapy (very low certainty).
1 finding from 1 review
Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults
S‐adenosyl methionine as monotherapy may leads to lower acceptability. Participants experiencing troublesome adverse effects… compared with tricyclic antidepressant agent (low certainty).
1 finding from 1 review
Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found